SCHEMBL4876203

SCHEMBL4876203

Oc1ccc(Cc2nc(-c3ccc4ncccc4c3)c(-c3ccccn3)[nH]2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TGFBR1 P36897 11/20 0.59
MAPK14 Q16539 3/20 0.59
KDR P35968 2/20 0.59
PDGFRA P16234 1/20 0.59
FLT1 P17948 1/20 0.59
FLT4 P35916 1/20 0.59
PRKD1 Q15139 1/20 0.59
RIPK2 O43353 1/20 0.47
ACVR1B P36896 1/20 0.47
TGFBR2 P37173 1/20 0.43
GAA P10253 1/20 0.43
PKM P14618 1/20 0.43
TSHR P16473 1/20 0.43
CBFB Q13951 2/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
POLB P06746 1/20 0.41
GRIN1 Q05586 1/20 0.40
GRIN2B Q13224 1/20 0.40
MET P08581 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4867750 0.90 TGFBR1 (0.65) TGFBR1MAPK14KDRPDGFRAFLT1
SCHEMBL7946514 0.90 TGFBR1 (0.57) TGFBR1MAPK14KDRPDGFRAFLT1
SCHEMBL3181381 0.90 TGFBR1 (0.57) TGFBR1MAPK14KDRPDGFRAFLT1
SCHEMBL4875136 0.89 TGFBR1 (0.71) TGFBR1MAPK14KDRPDGFRAFLT1
SCHEMBL4876116 0.87 TGFBR1 (0.56) TGFBR1MAPK14KDRPDGFRAFLT1
SCHEMBL4877766 0.84 TGFBR1 (0.66) TGFBR1MAPK14KDRPDGFRAFLT1
SCHEMBL4874162 0.82 TGFBR1 (0.85) TGFBR1MAPK14KDRPDGFRAFLT1
SCHEMBL4872666 0.81 TGFBR1 (0.83) TGFBR1MAPK14KDRPDGFRAFLT1
SCHEMBL4867779 0.81 TGFBR1 (0.62) TGFBR1MAPK14KDRPDGFRAFLT1
SCHEMBL4872136 0.80 TGFBR1 (0.76) TGFBR1MAPK14KDRPDGFRAFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130245066-A1 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors IN2GEN CO., LTD. (KR) 2013-09-19 US claimed
US-20080319012-A1 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors IN2GEN CO., LTD. (KR) 2008-12-25 US claimed
US-20130245066-A1 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors IN2GEN CO., LTD. (KR) 2013-09-19 US disclosed
US-20130245066-A1 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors IN2GEN CO., LTD. (KR) 2013-09-19 US disclosed
US-20130245066-A1 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors IN2GEN CO., LTD. (KR) 2013-09-19 US disclosed
US-20080319012-A1 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors IN2GEN CO., LTD. (KR) 2008-12-25 US disclosed
US-20080319012-A1 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors IN2GEN CO., LTD. (KR) 2008-12-25 US disclosed
US-20080319012-A1 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors IN2GEN CO., LTD. (KR) 2008-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130245066-A1 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors ALK, ERBB4, ACVR1 TGFBR1 93/4885MAPK14 478/4885KDR 9/4885
US-20080319012-A1 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors ALK, ERBB4, ACVR1 TGFBR1 93/4885MAPK14 478/4885KDR 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.